Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights

References

• World Health Organization. High levels of antibiotic resistance found worldwide, new data shows. WHO; [cited 2018 Nov 30]. Available from: https://www.who.int/mediacentre/news/releases/2018/antibiotic-resistance-found/en/
   Google Scholar
• de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016;13:e1002184.
   PubMed Web of Science ®Google Scholar
• Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42:S82–9.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–327.
   PubMed Web of Science ®Google Scholar
• Rello J, Kalwaje Eshwara V, Conway-Morris A; TOTEM Study Investigators, et al. Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey. Eur J Clin Microbiol Infect Dis. 2019; Epub ahead of print. doi:10.1007/s10096-019-03530-1
   Web of Science ®Google Scholar
• Rello J, Kalwaje Eshwara V, Lagunes L, et al. A global priority list of the TOp TEn resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis. Eur J Clin Microbiol Infect Dis. 2019;38(2):319–323.
   PubMed Web of Science ®Google Scholar
• Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis. 2016;16:239–251.
   PubMed Web of Science ®Google Scholar
• Rolain J-M, Abat C, Jimeno M-T, et al. Do we need new antibiotics? Clin Microbiol Infect. 2016;22:408–415.
   PubMed Web of Science ®Google Scholar
• Coates ARM, Hu Y. Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol. 2007;152:1147–1154.
   PubMed Web of Science ®Google Scholar
• Rello J, Bunsow E, Perez A. What if there were no new antibiotics? A look at alternatives. Expert Rev Clin Pharmacol. 2016;9:1547–1555.
   PubMed Web of Science ®Google Scholar
• Xbiotech. MRSA antibody therapy. [cited 2018 Nov 5]. Available from: http://www.xbiotech.com/clinical/mrsa.html
   Google Scholar
• Hua L, Cohen TS, Shi Y, et al. MEDI4893* promotes survival and extends the antibiotic treatment window in a staphylococcus aureus immunocompromised pneumonia model. Antimicrob Agents Chemother. 2015;59:4526–4532.
   PubMed Web of Science ®Google Scholar
• Yu X-Q, Robbie GJ, Wu Y, et al. Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob Agents Chemother. 2016;61(1):e01020–16.
   PubMed Web of Science ®Google Scholar
• François B, Mercier E, Gonzalez C, et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Med. 2018;44:1787–1796.
   PubMed Web of Science ®Google Scholar
• Rouha H, Weber S, Janesch P, et al. Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies. Virulence. 2018;9:231–247.
   PubMed Web of Science ®Google Scholar
• Huynh T, Stecher M, Mckinnon J, et al. Safety and tolerability of 514G3, a true human anti-protein a monoclonal antibody for the treatment of S. aureus bacteremia. Open Forum Infect Dis. 2016;3(1):1354.
   Google Scholar
• Jain R, Beckett VV, Konstan MW, et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. J Cyst Fibros. 2018;17:484–491.
   PubMed Web of Science ®Google Scholar
• Ali SO, Yu XQ, Robbie GJ, et al. Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin Microbiol Infect. 2019;25(5):629.e1-629.e6.
   Web of Science ®Google Scholar
• Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection. N Engl J Med. 2017;376:305–317.
   PubMed Web of Science ®Google Scholar
• Begier E, Seiden DJ, Patton M, et al. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Vaccine. 2017;35:1132–1139.
   PubMed Web of Science ®Google Scholar
• Pipeline Review. The biologics news and reports portal. [cited 2018 Nov 5] Available from: https://pipelinereview.com/
   Google Scholar
• Chen WH, Pasetti MF, Adhikari RP, et al. Safety and Immunogenicity of a parenterally administered, structure-based rationally modified recombinant staphylococcal enterotoxin B protein vaccine, stebvax. Burns DL, editor. Clin Vaccine Immunol. 2016;23:918–925.
   PubMed Web of Science ®Google Scholar
• Landrum ML, Lalani T, Niknian M, et al. Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant panton-valentine leukocidin subunit, in healthy adults. Hum Vaccin Immunother. 2017;13:791–801.
   PubMed Web of Science ®Google Scholar
• Roetzer A, Jilma B, Eibl MM. Vaccine against toxic shock syndrome in a first-in-man clinical trial. Expert Rev Vaccines. 2017;16:81–83.
   PubMed Web of Science ®Google Scholar
• Rello J, Krenn C-G, Locker G, et al. A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients. Crit Care. 2017;21:22.
   PubMed Web of Science ®Google Scholar
• Valneva. Valneva provides update on Phase II/III interim analysis of its Pseudomonas aeruginosa vaccine candidate. 2013. [cited 2018 Nov 17]. Available from: https://www.valneva.com/en/
   Google Scholar
• Torres-Barceló C. The disparate effects of bacteriophages on antibiotic-resistant bacteria. Emerg Microbes Infect. 2018;7:168.
   PubMed Web of Science ®Google Scholar
• Kim N-H, Park WB, Cho JE, et al. Effects of phage endolysin SAL200 combined with antibiotics on Staphylococcus aureus infection. Antimicrob Agents Chemother. 2018;62(10):e00731–18.
   PubMed Web of Science ®Google Scholar
• Jun SY, Jang IJ, Yoon S, et al. Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrob Agents Chemother. 2017;61(6):e02629–16.
   PubMed Web of Science ®Google Scholar
• Fischetti V. Development of phage lysins as novel therapeutics: a historical perspective. Viruses. 2018;10:310.
   Web of Science ®Google Scholar
• Chopra S, Harjai K, Chhibber S. Potential of combination therapy of endolysin MR-10 and minocycline in treating MRSA induced systemic and localized burn wound infections in mice. Int J Med Microbiol. 2016;306:707–716.
   PubMed Web of Science ®Google Scholar
• Keary R, Sanz-Gaitero MJ, van Raaij M O, et al. Characterization of a bacteriophage-derived murein peptidase for elimination of antibiotic-resistant staphylococcus aureus. Curr Protein Pept Sci. 2016;17:183–190.
   PubMed Web of Science ®Google Scholar
• Oliveira H, Vilas Boas D, Mesnage S, et al. Structural and enzymatic characterization of ABgp46, a novel phage endolysin with broad anti-gram-negative bacterial activity. Front Microbiol. 2016;7:208.
   PubMed Web of Science ®Google Scholar
• Chan BK, Turner PE, Kim S, et al. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health. 2018;2018(1):60–66.
   PubMed Web of Science ®Google Scholar
• Hoffman LR, D’Argenio DA, MacCoss MJ, et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature. 2005;436:1171.
   PubMed Web of Science ®Google Scholar
• Merabishvili M, Pirnay J-P, Verbeken G, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One. 2009;4:e4944.
   PubMed Web of Science ®Google Scholar
• Jennes S, Merabishvili M, Soentjens P, et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care. 2017;21:129.
   PubMed Web of Science ®Google Scholar
• Leitner L, Sybesma W, Chanishvili N, et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol. 2017;17(1):90.
   PubMed Web of Science ®Google Scholar
• Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61(10):e00954–17.
   PubMed Web of Science ®Google Scholar
• Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19(1):35–45.
   PubMed Web of Science ®Google Scholar
• Azeredo Da Silveira S, Perez A. Liposomes as novel anti-infectives targeting bacterial virulence factors? Expert Rev Anti Infect Ther. 2015;13:531–533.
   PubMed Web of Science ®Google Scholar
• Azeredo Da Silveira S, Perez A. CAL02 liposomes and other antitoxins: a new generation of anti-infectives. Clin Pulm Med. 2018;25:84–88.
   Google Scholar
• Laterre P-F, Colin G, Dequin P. First-in-human double-blind placebo-controlled randomised study with CAL02, a novel anti-toxin liposomal agent, in severe pneumococcal pneumonia. Lancet Infect Dis. 2019. Epub Ahead of print. DOI:10.1016/S1473-3099(18)30805-3
   PubMed Web of Science ®Google Scholar
• Pletz MW, Bauer M, Brakhage AA. One step closer to precision medicine for infectious diseases Epub Ahead of print. Lancet Infect Dis. 2019. doi:10.1016/S1473-3099(19)30070-2.
   PubMed Web of Science ®Google Scholar
• Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154–162.
   PubMed Web of Science ®Google Scholar
• Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3:24–32.
   PubMed Web of Science ®Google Scholar
• Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67:1803–1814.
   PubMed Web of Science ®Google Scholar